BioGaia Invests In Development Of A Drug Against NEC
The board of BioGaia (STO:BIOG-B) has decided to invest in the first phase of a long-term project aimed at developing a drug with rigorous hygiene, analysis and documentation requirements, to treat the highly fatal disease Necrotising Enterocolitis (NEC), which affects premature infants.
Help employers find you! Check out all the jobs and post your resume.